Menu Search
Equities

ALK-Abello A/S

ALK B:CPH

ALK-Abello A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)178.00
  • Today's Change0.00 / 0.00%
  • Shares traded136.65k
  • 1 Year change+117.60%
  • Beta1.1602
Data delayed at least 15 minutes, as of Sep 18 2024 16:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy3
Outperform1
Hold2
Sell0
Strong Sell0

Share price forecast in DKK

The 6 analysts offering 12 month price targets for ALK-Abello A/S have a median target of 171.00, with a high estimate of 200.00 and a low estimate of 150.00. The median estimate represents a -3.93% decrease from the last price of 178.00.
High12.4%200.00
Med-3.9%171.00
Low-15.7%150.00

Earnings history & estimates in DKK

On Aug 22, 2024, ALK-Abello A/S reported 2nd quarter 2024 earnings of 0.90 per share. This result exceeded the 0.600 expectation of the one analyst covering the company and exceeded last year's 2nd quarter results by 0.600.
The next earnings announcement is expected on Nov 14, 2024.
Average growth rate+36.41%
ALK-Abello A/S reported annual 2023 earnings of 2.20 per share on Feb 08, 2024.
Average growth rate+289.12%
More ▼

Revenue history & estimates in DKK

ALK-Abello A/S had 2nd quarter 2024 revenues of 1.37bn. This bettered the 1.31bn consensus of the 2 analysts covering the company. This was 11.35% above the prior year's 2nd quarter results.
Average growth rate+5.28%
ALK-Abello A/S had revenues for the full year 2023 of 4.82bn. This was 6.94% above the prior year's results.
Average growth rate+10.23%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.